Welcome to our dedicated page for Bio-Path Holdings news (Ticker: BPTH), a resource for investors and traders seeking the latest updates and insights on Bio-Path Holdings stock.
Bio-Path Holdings Inc. (NASDAQ: BPTH) is a pioneering biotechnology company focused on developing innovative therapeutic products through its proprietary DNAbilize® technology. This technology enables the delivery of nucleic acid drugs throughout the human body via simple intravenous infusion. Bio-Path's primary focus is on oncology, aiming to provide effective treatments for various forms of cancer.
The company's lead product candidate, prexigebersen (BP1001), is currently in Phase II clinical trials for Acute Myeloid Leukemia (AML) in combination with low-dose cytarabine (LDAC) and decitabine. Additionally, Bio-Path is exploring prexigebersen's potential in combination with dasatinib for patients with blast-phase and accelerated-phase Chronic Myeloid Leukemia (CML).
Another key candidate, BP1002, targets the Bcl-2 protein, which plays a crucial role in cell survival for many cancers. BP1002 is being evaluated for its effectiveness against lymphoma and solid tumors, offering hope for venetoclax-resistant AML patients. The company's technological advantage lies in its DNAbilize® platform, a liposomal antisense DNA method that significantly improves oligonucleotide therapeutics' delivery and efficacy.
Bio-Path Holdings continues to expand its pipeline with additional candidates such as BP1003, a STAT3 antisense oligodeoxynucleotide, and BP1001-A, a modification designed for solid tumors. These developments emphasize the company's commitment to addressing unmet medical needs in oncology.
Recently, Bio-Path has made significant strides in its clinical programs, receiving positive feedback from the U.S. FDA and advancing its trials at renowned institutions including Weill Cornell Medical College and The University of Texas MD Anderson Cancer Center. The company maintains a robust intellectual property portfolio to protect its innovative DNAbilize® platform.
For investors and stakeholders, Bio-Path Holdings represents a forward-thinking entity with a strategic focus on developing novel RNAi nanoparticle drugs. The company's advancements in the clinical and preclinical stages underline its potential to make substantial contributions to cancer treatment paradigms.
Bio-Path Holdings (NASDAQ:BPTH) reported its financial results for 2022, showing a net loss of $13.9 million or $1.91 per share, compared to a loss of $10.4 million the previous year. Research and development expenses rose to $9.2 million, attributed to increased clinical trial activities. As of December 31, 2022, the company had $10.4 million in cash, a decrease from $23.8 million in 2021. Key clinical milestones include the first patient dosed in the BP1001-A Phase 1/1b trial for solid tumors and ongoing trials for AML. The company remains optimistic about progressing through its 2023 milestones.
Bio-Path Holdings, Inc. (NASDAQ: BPTH) will host a live conference call and audio webcast on March 31, 2023, at 8:30 a.m. ET to discuss its financial results for Q4 and the full year ending December 31, 2022. The company specializes in developing targeted nucleic acid cancer drugs using its proprietary DNAbilize® technology. Bio-Path's lead candidate, prexigebersen, is in a Phase 2 study for blood cancers, while another candidate, BP1002, is being evaluated for various cancers. The call will also include a business overview, and access details are provided for both domestic and international participants.
FAQ
What is the current stock price of Bio-Path Holdings (BPTH)?
What is the market cap of Bio-Path Holdings (BPTH)?
What is Bio-Path Holdings Inc. known for?
What is DNAbilize® technology?
What is prexigebersen (BP1001)?
What is BP1002 and what does it target?
Which institutions are involved in Bio-Path's clinical trials?
What is the potential advantage of BP1002 over current treatments?
What are the main benefits of DNAbilize® technology for patients?
What is BP1003 and what does it target?
How does Bio-Path Holdings protect its innovations?
How can investors get more information about Bio-Path Holdings?
